KR20220032610A - Cmv 감염과 관련된 질병 치료를 위한 융합 독소 단백질 - Google Patents

Cmv 감염과 관련된 질병 치료를 위한 융합 독소 단백질 Download PDF

Info

Publication number
KR20220032610A
KR20220032610A KR1020227004798A KR20227004798A KR20220032610A KR 20220032610 A KR20220032610 A KR 20220032610A KR 1020227004798 A KR1020227004798 A KR 1020227004798A KR 20227004798 A KR20227004798 A KR 20227004798A KR 20220032610 A KR20220032610 A KR 20220032610A
Authority
KR
South Korea
Prior art keywords
leu
ala
immunotoxin
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227004798A
Other languages
English (en)
Korean (ko)
Inventor
토마스 닛슈케 크레달
메테 마리에 로센킬데
Original Assignee
쾨벤하운스 유니버시테트
덴마크스 텍니스케 유니버시테트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쾨벤하운스 유니버시테트, 덴마크스 텍니스케 유니버시테트 filed Critical 쾨벤하운스 유니버시테트
Publication of KR20220032610A publication Critical patent/KR20220032610A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227004798A 2019-07-12 2020-06-25 Cmv 감염과 관련된 질병 치료를 위한 융합 독소 단백질 Ceased KR20220032610A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19186000 2019-07-12
EP19186000.6 2019-07-12
PCT/EP2020/067785 WO2021008840A1 (en) 2019-07-12 2020-06-25 Fusion toxin proteins for treatment of diseases related to cmv infections

Publications (1)

Publication Number Publication Date
KR20220032610A true KR20220032610A (ko) 2022-03-15

Family

ID=67437717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227004798A Ceased KR20220032610A (ko) 2019-07-12 2020-06-25 Cmv 감염과 관련된 질병 치료를 위한 융합 독소 단백질

Country Status (10)

Country Link
US (1) US20220281933A1 (https=)
EP (1) EP3997107A1 (https=)
JP (1) JP2022540877A (https=)
KR (1) KR20220032610A (https=)
CN (1) CN114206944A (https=)
AU (1) AU2020312560A1 (https=)
BR (1) BR112022000417A2 (https=)
CA (1) CA3146798A1 (https=)
MX (1) MX2022000433A (https=)
WO (1) WO2021008840A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2603166A (en) * 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
EP4301394A1 (en) * 2021-03-03 2024-01-10 Synklino ApS Compositions for ex vivo organ care

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003327A2 (en) 2006-07-03 2008-01-10 Inagen Aps Immunotoxins for the treatment of diseases related to cmv infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018954A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
CA2437201C (en) * 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP3262063B1 (en) * 2015-02-26 2021-09-22 Var2 Pharmaceuticals ApS Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
US10849960B2 (en) * 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003327A2 (en) 2006-07-03 2008-01-10 Inagen Aps Immunotoxins for the treatment of diseases related to cmv infection

Also Published As

Publication number Publication date
MX2022000433A (es) 2022-04-25
US20220281933A1 (en) 2022-09-08
BR112022000417A2 (pt) 2022-03-03
EP3997107A1 (en) 2022-05-18
CN114206944A (zh) 2022-03-18
CA3146798A1 (en) 2021-01-21
WO2021008840A1 (en) 2021-01-21
AU2020312560A1 (en) 2022-03-03
JP2022540877A (ja) 2022-09-20

Similar Documents

Publication Publication Date Title
KR101413480B1 (ko) Ｓｐａｒｃ 결합 펩티드와 이들의 용도
CA2325341C (en) Mutagenized il13-based chimeric molecules
RU2679889C2 (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP6675394B2 (ja) 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
CA2953827A1 (en) Compositions and methods of use for treating metabolic disorders
KR20150121715A (ko) Ｃｓｆ１ 치료제
JP2016531088A (ja) ５ｔ４標的化免疫融合分子および方法
CN108430511A (zh) 一种药物设计方法和获得的药物及其应用
CN116440285A (zh) 冠状病毒多肽类融合抑制剂的长效化的方法
KR20220032610A (ko) Cmv 감염과 관련된 질병 치료를 위한 융합 독소 단백질
US20220242964A1 (en) Compositions and methods for regulating erythropoiesis
EP1636263B1 (en) Pegylated soluble gp130-dimers useful as a medicament
CN101070350A (zh) 针对cd13的靶向肽与力达霉素构成的强化融合蛋白ngr－ldp－ae
CN101914161A (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
CN101684159B (zh) 人颗粒酶b蛋白衍生物及其在靶向治疗腺癌中的用途
CN108295242B (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
JP7668785B2 (ja) 融合タンパク質およびその使用
WO2023170209A1 (en) Fusion proteins and uses thereof
CN102775496A (zh) 靶向清除hiv/siv的复合药物
CN113121668B (zh) PEG修饰的可抑制gp96的多肽、其制备方法及用途
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
CN113842467A (zh) 用于抗体与药物偶联体（adc）制备的中间体及其制备方法和应用
KR20130033273A (ko) 항 ｉｇｆ-1ｒ 단일클론 항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
KR20260024531A (ko) 암 배아 항원에 특이적으로 결합하는 항원 결합 단백질 또는 나노바디, 이를 포함하는 융합 단백질 및 이의 암 치료 용도
CN117683140A (zh) 肿瘤靶向的以白介素2为活性成分的融合蛋白型药物前体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601